Pronto disponible para inscripción

This study will open for enrollment soon. Please contact the study team for more information and check back frequently.

ALXN2023 - CONCORD (Antibody-Mediated Rejection after Kidney Transplant) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if an experimental drug called ALXN2030 (the study drug) is a safe and effective option for people diagnosed with antibody-mediated rejection (AMR) of a transplanted kidney.

What is the Condition Being Studied?

Antibody-Mediated Rejection (AMR) of a Kidney After Transplant

Who Can Participate in the Study?

Adults ages 18-75 who:

Are diagnosed with active or chronic active AMR
Are vaccinated against meningococcal infection, pneumonia, and influenza

For more information, contact the study team at hanajoy.porter@duke.edu.

Grupo etario

Adultos

What is Involved?

If you choose to join this study, you will get a random assignment to either:

Get the study drug; OR
Get a placebo (inactive substance with no drug in it)

The study drug or placebo is given as an intravenous (IV) infusion every 3 months. Participation in the study will last for about 3 years.

Study Details

Full Title

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN2030 in Adult Patients with Antibody-Mediated Rejection after Kidney Transplantation

Principal Investigator